Treatment and prevention of sudden cardiac death - What have we learnt from randomised clinical trials?

Singapore Medical Journal

Volumn 40, Issue 11, 1999, Pages 707-710

  Kam, R M L ^a   Teo, W S ^a   Koh, T H ^a   Lim, Y L ^a  

^a DEPARTMENT OF CARDIOLOGY   (Singapore)

Author keywords

Antiarrhythmic drugs; Cost effectiveness; Implantable cardioverter defibrillator; Sudden death; Survival

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; SOTALOL;

CARDIOVERSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEFIBRILLATOR; DRUG MECHANISM; GENE THERAPY; HEART FAILURE; HEART INFARCTION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; RANDOMIZED CONTROLLED TRIAL; REVIEW; SUDDEN DEATH; SYNCOPE;

ADRENERGIC BETA-ANTAGONISTS; ANTI-ARRHYTHMIA AGENTS; CLINICAL TRIALS; COST-BENEFIT ANALYSIS; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; EVIDENCE-BASED MEDICINE; HEALTH CARE COSTS; HUMANS; MYOCARDIAL INFARCTION; PROGNOSIS;

EID: 0033429062     PISSN: 00375675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Bayes de Luna, Coumel P, Leclerq JF. Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmias on the basis of data from 157 cases. Am Heart J 1989; 117:151-9.
2. Cobb LA, Baum RS, Alvarez H, Schaffen WA. Resuscitation from out-of-hospital ventricular fibrillation; 4 years follow-up. Circulation 1975; 52: III 223-35.
3. Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction, I: mortality results. JAMA 1982; 247:1707-14.
4. Chadda K, Goldstein S, Byington R, Curb JD. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation 1986; 73:503-10.
5. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321:406-12.
6. The Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992; 327:227-33.
7. Waldo A, Camm JA, de Ruyter H, Friedman PL, MacNeil DJ, Pitt B. Survival with oral d-sotalol in patients with left ventricular dysfunction after myocardial infarction: rationale, design and methods (the SWORD Trial). J Am Coll Cardiol 1995; 75:1023-7.
8. Julian D, Camm A, Frangin G, Janse M, Schwartz P, Simon P, for the European Myocardial Infarct Amiodarone Trial Investigators. Randomized trial of effect of amiodarone on mortality in patients with left ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997; 349:667-74.
9. Cairns JA, Connolly SJ, Roberts R, Gent M, for the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Randomized trial of outcome after myocardial infarction in patients with frequent or repetitive premature depolarizations: CAMIAT. Lancet 1997; 349:675-82.
10. Singh S, Fletcher R, Fisher S, Singh B. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia: Survival Trial of Amiodarone in Patients with Congestive Heart Failure. N Engl J Med 1995; 333:77-82.
11. Doval HC, Nul DL, Grancelli HO, Perrone SV, Bortman GR, Curiel R. Randomized trial of low dose amiodarone in severe congestive heart failure. Lancet 1994; 344:493-8.
12. The CASCADE Investigators. Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE Study). Am J Cardiol 1993; 72:280-7.
13. Mason JW for the Electrophysiologic Study Versus Electrocardiographic Monitoring Investigators. A comparison of electrophysiologic testing with Holter monitoring to predict antiarrhythmic drug efficacy for ventricular tachyarrhythmias. N Engl J Med 1993; 329:445-51.
14. Moss A, Hall J, Cannom D, Daubert J, Higgins S, Klein H, et al for the Multicenter Automatic Defibrillator Implantation Trial. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996; 335: 1933-40.
15. The Antiarrhythmics Versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997; 337:1576-83.
16. Connolly S, Gent M, Roberts R, Dorian P, Green MS, Klein GJ, et al. Canadian Implantable Defibrillator Study (CIDS): study design and organization. Am J Cardiol 1993; 72:103F-8F.
17. Siebels J, Cappato R, Ruppel R, Schneider MA, Kuck K and the CASH Investigators. Preliminary results of the Cardiac Arrest Study Hamburg (CASH). Am I Cardiol 1993; 72:109F-13F.
18. The CABG Parch Trial Investigators and Coordinators. The Coronary Artery Bypass Graft (CABG) Patch Trial. Prog Cardiovasc Dis 1993; 36:97-114.
19. Buxton AE, Fisher JD, Josephson M, Lee K, Pryor DB, Prystowsky EN, et al. Prevention of sudden death in patients with coronary artery disease: the Multicenter Unsustained Tachycardia Trial (MUSTT). Prog Cardiovasc Dis 1993; 36:215-26.
20. The Prevention of Sudden Cardiac Death in Heart Failure Trial. Washington, DC: NIH Physician Pamphlet; 1997. National Institutes of Health.
21. Goldman L, Gordon DJ, Rifkind BM. Cost and health implications of cholesterol lowering. Circulation 1992; 85:1960-8.
22. Kuppermann M, Luce BR, McGovern B, Podrid PJ, Bigger JT, Ruskin JN. An analysis of the cost effectiveness of the implantable defibrillator. Circulation 1990; 81:91-100.
23. Wever EFD, Hauer RNW, Schrijvers G, Van Capelle FJL, Tijssen JGP, Crijns HJGM, et al. Cost-effectiveness of implantable defibrillator as first choice therapy versus electrophysiologically guided tiered strategy in post-infarct sudden death survivors. Circulation 1996; 93:489-96.
24. Larsen GC, Manolis AC, Sonnenberg FA, Beshansky JR, Estes NAM, Pauker SG. Cost effectiveness of the implantable defibrillator: effect of improved battery life and comparison with amiodarone therapy. J Am Coll Cardiol 1992; 19:1323-34.
25. Kuppersmith J, Hogan A, Guerrero P, Gardiner J, Mellits ED, Baumgardner R, et al. Evaluating and improving the cost effectiveness of the implantable cardioverter-defibrillator. Am Heart J 1995; 130:507-15.
26. Owens DK, Sanders GD, Harris RA, McDonald KM, Heidenreich PA, Dembitzer AD, et al. Cost-effectiveness of implantable cardioverter-defibrillator relative to amiodarone for the prevention of sudden cardiac death. Ann Intern Med 1997; 126:1-12.
27. Valenti R, Schlapfer J, Fromer M, Fischer A, Kappenberger E. Impact of the implantable cardioverter-defibrillator on rehospitalizations. Eur Heart J 1996; 17: 1565-71.